Abstract-Pulmonary arterial hypertension is a fatal lung disease caused by the progressive remodeling of small pulmonary arteries (PAs). Sildenafil can prevent the remodeling of PAs, but conventional sildenafil formulations have shown limited treatment efficacy for their poor accumulation in PAs. Here, glucuronic acid (GlcA)-modified liposomes (GlcA-Lips) were developed to improve the delivery of sildenafil to aberrant over-proliferative PA smooth muscle cells via targeting the GLUT-1 (glucose transport-1), and, therefore, inhibiting the remodeling of PAs in a monocrotaline-induced PA hypertension model. GlcA-Lips encapsulating sildenafil (GlcA-sildenafil-Lips) had a size of 90 nm and a pH-sensitive drug release pattern. Immunostaining assay indicated the overexpression of GLUT-1 in PA smooth muscle cells. Cellular uptake studies showed a 1-fold increase of GlcA-Lips uptake by PA smooth muscle cells and pharmacokinetics and biodistribution experiments indicated longer blood circulation time of GlcA-Lips and increased ability to target PAs by 1-fold after 8 hours administration. Two-week treatment indicated GlcA-sildenafil-Lips significantly inhibited the remodeling of PAs, with a 32% reduction in the PA pressure, a 41% decrease in the medial thickening, and a 44% reduction of the right ventricle cardiomyocyte hypertrophy, and improved survival rate. Immunohistochemical analysis showed enhanced expression of caspase-3, after administration of GlcA-sildenafil-Lips, and reduced expression of P-ERK1/2 (phosphorylated ERK1/2) and HK-2 (hexokinase-2), and increased level of eNOS (endothelial nitric oxide synthase) and cyclic GMP (cGMP). In conclusion, targeted delivery of sildenafil to PA smooth muscle cells with GlcALips could effectively inhibit the remodeling of PAs in the monocrotaline-induced PA hypertension. (Hypertension.
P ulmonary arterial hypertension (PAH) occurs either in idiopathic form or in association with diseases, such as congenital heart malformation, connective tissue disease, or HIV infection. It is typically characterized by increased pulmonary vascular resistance, vascular remodeling caused syncope, dyspnea on exertion, right heart failure, and even premature death. 1, 2 The mechanism of vascular remodeling has been intensively investigated but has not yet been completely elucidated. Currently, inducing apoptosis or suppressing proliferation of vascular cells is still the mainstay for the treatment of PAH, based on the apoptotic resistance theory. 3 This theory was proposed to be involved in the hyperplasia of pulmonary vascular cells, which contributes to the formation of the neointimal lesions and medial thickening of the small pulmonary arteries (PAs).
Conversely, several research groups have reported that inhibiting the apoptosis of endothelial cells, by upregulating angiopoietin or through targeting delivery of antioxidant, 4, 5 allowed for the protective effect on the pulmonary vasculature regression. [6] [7] [8] Central to these apparent contradicting results is the fact that pulmonary vascular remodeling exhibits spatiotemporal diversity as PAH develops, with coexistence of both proliferative vascular cells and apoptotic endothelial cells susceptible to noxious stimuli (ie, shear stress or toxin). 9, 10 Because of the inhomogeneous distribution of vascular remodeling or cell viability conditions in small PAs, patients with intractable PAH require cell-specific or vascular compartment-specific therapies. Therefore, a pro-apoptotic therapeutic strategy that targets only to the proliferating cells, while avoiding injury to the normal or apoptotic cells, could provide an effective treatment of PAH.
Pathologically, the progressive thickening of PAs is mainly caused from the increased proliferation and migration of smooth muscle cells (SMCs). 11 In addition, the glycolytic activity in the lungs of PAH patients is more active than in other tissues. Restoring the oxidative phosphorylation in glycolytic SMCs could actually lead to the regression of many forms of pulmonary hypertension. 12, 13 The upregulated glycolytic process in the lungs of PAH patients has also been confirmed by clinical studies, using positron emission tomography-computed tomography scanning. Moreover, the activation of GLUT-1 (glucose transport-1) has been identified to account for the increased uptake of glucose in those remodeled PAs.
14 Therefore, the preferential uptake of glucose in the glycolytic PAs of PAH patients can be used as a promising noninvasive diagnostic tool to evaluate PAH development but also be exploited to facilitate the intracellular trafficking of drugs to the site of interest.
Accordingly, in this study, we hypothesized that GLUT-1 is overexpressed on PA smooth muscle cells (PASMCs), and by targeting the GLUT-1, a pro-apoptotic drug could be delivered to SMCs more efficiently, inhibiting the proliferation of SMCs and reversing PAH. To verify our hypothesis, GlcA (glucuronic acid) was firstly used to modify a classic drug carrier, liposomes (Lips), which have been recognized as one of the most successful drug delivery system for the detection and treatment of diverse diseases. More than 7 liposomes based products have been approved for use in clinical applications. 15 Sildenafil, a selective phosphodiesterase V inhibitor, was then selected as a model drug to be encapsulated into the modified liposomes. It can prevent the remodeling of PAs by inhibiting SMC proliferation as well as perivascular inflammation in monocrotaline-induced PAH model. 16 
Experimental Methods
The authors declare that all supporting data are available within the article (and in the online-only Data Supplement). Following details are provided in the online-only Data Supplement: 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-(polyethylene glycol)-2000-GlcA, DSPE-PEG2000-GlcA), nanoparticle preparation, preparation of monocrotaline model, administration of preparations to animals, isolation of PASMCs, pharmacokinetic study, in vivo 18-FDG positron emission tomography, echocardiographic measurements, Western blot analysis, and statistical analysis. All experiments were performed with approval from the Committee of Nanjing University Medical School for Laboratory Animal Care and Use (Nanjing, China). Most of the experimental design in vitro and in vivo referred to the Standardized Protocols described by Bonnet et al.
17,18

Preparation of GlcA-Lips
Liposomes were prepared via a hydration method. Briefly, lipid materials (S100, dioleoyl phosphoethanolamine [DOPE], cholesterol, and DSPE-PEG2000-GlcA) were dissolved at a mass ratio of 18:2:8:1 in chloroform, followed by removal of the organic phase under reduced pressure. Sildenafil-loaded liposomes were prepared by mixing the empty liposomes with sildenafil solution (4 mg/mL) at a mass ratio of 1:29 at 55°C for 10 minutes. Dye-loaded liposomes were prepared in a similar way, except that the dye dissolved together with the lipid materials in chloroform before the hydration process. The dyes including coumarin-6 (C6), fluorescein isothiocyanate (FITC), near-infrared fluorescence (IR-783), and tetramethylindotricarbocyanine iodide (DiR) were used in the study.
Biodistribution and Lung Targeting
For the biodistribution study, the monocrotaline-induced models (4 rats) were intravenously injected with DiR-labeled GlcA-Lips via the tail vein at a DiR dose of 0.5 mg/kg, according to the rats' body weight. At the predetermined time points, the rats were euthanized to collect their major organs, followed by in vivo imaging using an imaging system (IVIS Spectrum, PerkinElmer).
For the quantification of sildenafil in the rat's major organs, sildenafil preparations were intravenously injected in the monocrotaline-induced models (4 rats) via the tail vein and at a sildenafil dose of 8 mg/kg, according to the rats' body weight. At specific time intervals, the animals were euthanized for organ collection and analysis. After the extraction processes, the sildenafil content was determined using the high-performance liquid chromatography method described in the section Pharmacokinetic Study (in the online-only Data Supplement).
The colocalization of the GlcA-Lips with PA α-SMA (α-smooth muscle actin) in monocrotaline-induced models was studied using Leica Corp. IX 7 fluorescence microscopy (Leica Microsystems Inc). The rats received intravenous administration of IR783-Lips or GlcA-IR783-Lips at an IR783 dose of 0.5 mg/kg. Four hours after the treatment, the rats' lungs were extracted and stored in 10% formalin for further fluorescent imaging. Briefly, formalin fixed and paraffin embedded sections were cut into 2 μm, and then blocked for 15 minutes with 5% fetal bovine serum at room temperature. After removal of the excess serum, the sections were incubated overnight with a mouse anti-rat α-SMA monoclonal antibody at 5 µg/mL, followed by a 60 minutes incubation with FITC (diluted 1:200 with FITC buffer) and 15 minutes treatment with DAPI.
Direct Right Ventricle Pressure Measurements
At the end point of the studies described above, the rat's trachea was intubated following intraperitoneal injection of sodium phenobarbital, and mechanic ventilation was commenced. Pulmonary hemodynamic parameters were measured in the open chest by directly puncturing the right ventricle (RV) outflow tract and then advancing the catheter, that connected to a pressure transducer of an Eagle400 monitor (General Electric company, Fairfield, CT), into the pulmonary artery trunk. The RV systolic pressure and mean PA pressure were both recorded after 1 minute of stabilization.
Histopathologic and Immunohistochemical Analysis of Rat Lungs and Hearts
After the above treatments, all the rats were euthanized by exsanguination and sacrificed to collect their lungs and hearts. The right low lobes of lungs were dissected, snap-frozen and maintained at a temperature of −80°C until further analysis.
Histological changes of the PAs and hearts were quantified by morphometry. Isolated lungs were inflated via the trachea with 10% formalin solution at 20 cm H 2 O pressure and fixed in 10% formalin. The degree of remodeling (muscularization) of small and peripheral PAs was assessed by immunohistochemical staining of 5 μm sections with an anti-α-SMA antibody (1:500 dilution; clone 1A4, Dako, Glostrup, Denmark). In each lung section, 10 small PAs (50-200 μm in diameter) and the mean area of cardiomyocytes were analyzed at a 400× magnification in a blind manner. Medial wall thickness was expressed as the sum of 2 points of medial thickness/external diameter×100 (%). Slides were quenched in 3% hydrogen peroxide, and the antigen was retrieved using a pressure cooker in 10 mmol/L citrate buffer at pH 6. The slides were first blocked with serum followed by incubation with the primary antibody overnight at 4°C. Immunodetection of Ki67 or Caspase-3 (1:100 dilution; rabbit polyclonal; Abcam, Cambridge, United Kingdom) was performed with horseradish peroxidase-conjugated anti-rabbit secondary antibody (KPL, Gaithersburg, MD) and DAB stain (Dako, Glostrup, Denmark). The slides were hematoxylin counterstained. The primary antibody (Dako, Glostrup, Denmark) was omitted in the negative control for every group of slides.
Survival Analysis
The rats included in the interventional protocol (6 groups with 10 rats in each group) were prospectively followed-up for survival analysis. Spontaneous deaths were counted as events. Time to event data was plotted using the Kaplan-Meier method, with differences evaluated using the Log-rank test.
Results
Preparation and Characterization of GlcA-Lips
To actively target the liposomes with sildenafil to GLUT-1 overexpressed in PASMCs, we used GlcA as the targeting ligand instead of Glc. Glc does not have reactive groups for direct coupling with typically available polyethylene glycol (PEG) end group functionalities (-NH 2 , -COOH, -SH, -N 3 , etc) and its conjugation to PEG requires chemical modification of the anomeric carbon by direct glycosidation with a click moiety for example (eg, propargyl α-D-glucopyranoside). On the other, GlcA is a sugar acid formed by the oxidation of the C 6 carbon of glucose and is readily available. The free carboxylic group in GlcA can easily react with primary or secondary amines using carbodiimide chemistry ( Figure S1A in the online-only Data Supplement).
DSPE-PEG2000-GlcA was obtained through the amide condensation reaction, in which the carboxyl group (-COOH) of GlcA reacts with the amino group (-NH 2 ) of DSPE-PEG-NH 2 and forms a stable amide bond (-CONH-). To confirm the coupling of GlcA to DSPE-PEG2000-NH 2 , 1 H-NMR was performed which revealed the characteristic peak of -CONH-around 5.8 ppm in the spectrum of DSPE-PEG2000-GlcA ( Figure S1D ).
After obtaining DSPE-PEG2000-GlcA, the lipid formulation was optimized to prepare GlcA-Lips. First, the effect of the pH-sensitive DOPE lipid on the size and entrapment efficiency (EnTE%) of GlcA-Lips was studied. As shown in Figure S2A , no significant changes were observed on the size and EE (%) of the GlcA-Lips with the increasing addition of DOPE to the lipid formulation, from 0% to 12.9% (w/w, compared with the weight of the total lipid). Regardless of the DOPE amount added, all obtained GlcA-Lips presented an approximate size of 90 nm, as well as an excellent drug encapsulated efficiency (EnCE%) of up to 85% for a highly water-soluble drug (sildenafil). Second, the effect of DOPE on the drug release from the GlcA-Lips in a pH 5.5 medium was investigated. As displayed in Figure S2B , the drug release from GlcA-Lips increased with the incorporation of DOPE but reached its maximum when 6.9 % (w/w) DOPE was added to the formulation. Based on these observations, 6.9% (w/w) of DOPE was used in the GlcA-Lips formulations ( Figure S2C) .
Characterization of the GlcA-Lips prepared with optimized formulation showed GlcA-Lips with a spherical shape ( Figure S2E ) and a diameter of ≈90 nm ( Figure S2D ). These GlcA-Lips also showed pH-sensitive release behavior with faster drug release in acidic medium (pH 5.5 and pH 6.8), than at pH 7.4 ( Figure S2F ).
Establishment of Monocrotaline-Induced Models and Overexpression of GLUT-1
At the 7th, 14th, and 28th days following the monocrotaline administration in rats, comprehensive transthoracic echocardiography examinations were performed to assess the PA blood flow profile, as well as the left ventricle and RV hypertrophy. The parameter of pulmonary artery blood flow accelerating time was closely correlated with the mean PA pressure and was used as a surrogate for it. 19 The monocrotaline-treated rats showed reduced pulmonary artery blood flow accelerating time, increased wall thickness and RV chamber size, as well as an insignificant effect on the size of the left ventricle, compared with the control ( Figure 1A ; Table S1 ). Altogether, these results demonstrated the success of the monocrotaline-induced model.
Additionally, the expression level of GLUT-1 in both PAs and SMCs was examined via Western blot. Compared with the levels found in normal rats, the expression of GLUT-1 in the monocrotaline-induced model was significantly higher ( Figure 1B) . Positive GLUT-1 immunostaining was also detected in the medial layer of the monocrotaline-induced rats ( Figure 1C ). Moreover, the expression level of GLUT-1 was examined via positron emission tomography-computed tomography, as the overexpression level of GLUT-1 was assumed to be similar to the Warburg effect resulted from aerobic cytoplasmic glycolysis, which could lead to the increased 18-FDG uptake at disease sites. 20 As expected, the PAH rats were shown to possess higher 18-FDG uptake in lungs and RV, compared with normal rats ( Figure 1D ; Table  S1 ). Collectively, these results confirmed the overexpression of GLUT-1 in both PAs and SMCs in monocrotaline-induced model.
Enhanced Cellular Uptake via GLUT-1 Targeting
To improve the liposome's cellular uptake, they were modified with GlcA aimed at targeting the overexpressed GLUT-1 in SMCs. After 4 hour incubation with SMCs, the cellular uptake of GlcA-C6-Lips was ≈2-fold higher than for nontargeted liposomes (C6-Lips) at both 37°C ( Figure S3A ) and 4°C ( Figure S3B) , regardless of the liposome concentration. Moreover, the cellular uptake of GlcA-C6-Lips showed to be time-dependent in a period of 7 hours ( Figure S3C ). These results confirmed our hypothesis that the modification of the liposomes with a glucose analog (GlcA) could increase the cellular uptake of the liposomes by SMCs from PAs, owing to the affinity of glucose for GLUT-1 overexpressed in SMCs.
To further investigate the endocytic pathway of the liposomes in more detail, SMCs were first treated with different inhibitors to block the corresponding internalization routes, before being incubated with the C6-labeled liposomes. The uptake of both GlcA-C6-Lips and C6-Lips by SMCs was inhibited by cytochalasin-D, chlorpromazine, nocodazole, and NaN 3 + deoxyglucose, respectively ( Figure S3D and S3E), indicating that both types of liposomes entered the cells in an energy-dependent way via multi-endocytic routes, including macropinocytosis, clathrin-mediated endocytosis, as well as microtubule-related internalization.
The intracellular trafficking of the liposomes in SMCs was also determined. Confocal images ( Figure S4 ) show a stronger green fluorescence intracellularly for the GlcA-C6-Lips than for C6-Lips, once again confirming the enhanced cellular uptake of the targeted liposomes via the GlcA modification. Yellow punctuate fluorescence was also observed in the overlapped images after colocalization of the green fluorescence from the C6-labeled liposomes with the red fluorescence from the LysoTracker Red stained lysosomes of SMCs, implying that the endocytosis of the liposomes was lysosome-mediated.
Pharmacokinetics, Biodistribution, and Targeting to PAs in the Lungs
After intravenous injection, the blood circulation time of the GlcA-sildenafil-Lips is critical for achieving targeted drug accumulation at disease site in the lung vessels. [21] [22] [23] Pharmacokinetic studies of GlcA-sildenafil-Lips in rats showed higher plasma level of sildenafil after injection of the GlcA-sildenafil-Lips, compared with the injection of the free drug ( Figure S5) . Moreover, the biological half-life (t 1/2 ), mean resident time, and area under the concentration curve of sildenafil, were increased by 1-fold when injected in GlcAsildenafil-Lips, while the clearance of the drug was decreased by approximately 1-fold, in contrast to the injection of the free drug (Table S2 ). These results indicated that the GlcALips could extend the blood circulation of the drug, and thus improve the accumulation of the drug at the disease site in lung vessels.
Furthermore, ex vivo imaging was performed to investigate the biodistribution of DiR-labelled Lips in the monocrotaline-induced model, following intravenous injection. As displayed in Figure 2 , after 0.5 and 2 hours of the injection, GlcA-DiR-Lips exhibited stronger fluorescence in the lung than DiR-Lips, indicating enhanced accumulation in the lung. Additionally, following the injections of the various sildenafil preparations, the accumulation of sildenafil in different organs was quantified. Sildenafil was found distributed in all organs after injection, but the highest drug accumulation in the lung was from the GlcA-Lips ( Figure S6 ). These results suggest the ability of GlcA-Lips to target the lung.
To further determine the colocalization of the liposomes with tunica media in the remodeled small PAs, histopathologic examination of lung sections was performed 1 day after the instillation of the IR783-labeled Lips to the monocrotaline-induced models. As shown in Figure 3 , only the IR783-GlcA-Lips were well colocalized with the remodeled PAs, implying that the GlcA modification enabled the liposomes with the target capacity to the small PAs of the lung in the PAH model.
Inhibition of Vascular Remodeling and RV Hypertrophy in the Monocrotaline-Induced PAH
After a 2-week treatment, the PA pressure of monocrotaline-induced rats was reduced to 32.4% as a result of the treatment with GlcA-sildenafil-Lips preparation, followed by sildenafil-Lips with a 26.2% decrease and free sildenafil with a 17.6% reduction ( Figure 4A ). The medial thickening of PAs was also reduced by approximately 41.3% and 20.6% with the GlcA-sildenafil-Lips and sildenafil-Lips treatment, respectively, compared with the monocrotaline-induced model group (Figure 4B and 4C) . Furthermore, the treatment with GlcA-sildenafil-Lips led to more significant decrease in PA pressure and medial thickening of PAs as compared with sildenafil-Lips group (P<0.05). Moreover, the expression level of α-SMA in PAs of the monocrotaline-induced models after the different treatments was evaluated, as the overexpression of α-SMA has been recognized as a marker of Proliferative PASMCs. 24 Accordingly, the expression of α-SMA was downregulated after the treatment with sildenafil preparations, in particular with GlcA-sildenafil-Lips ( Figure 4D and 4E) .
RV hypertrophy is considered a key risk factor of PAH associated morbidity and mortality. 25 Therefore, the changes of RV cardiomyocyte in the monocrotaline-induced model after the treatment with different preparations were evaluated. Histopathologic examination detected significant attenuation of by the sildenafil-Lips, and GlcA-sildenafilLips preparation allowed for further amelioration of RV hypertrophy compared with sildenafil-Lips group (P<0.05; Figure 5A ), which was also confirmed in the quantitative assay ( Figure 5B ). Higher survival rates were also observed for rats in the group treated with sildenafil-Lips or GlcAsildenafil-Lips preparations, with the log-rank test P value of 0.0416 and 0.0016, respectively, compared with the monocrotaline-induced group without treatment ( Figure 5C ). 
Mechanistic Studies on the Regression of PAs in Monocrotaline-Models
After the treatment with different preparations, the proliferation of PASMCs in the PAs in rats was assessed. Both of Ki67, a cellular marker for proliferation, and caspase-3, a critical executioner for apoptosis, were used as the assessment indexes. As observed in Figure 6A , the group treated with the GlcA-sildenafil-Lips preparation expressed the lowest level of Ki67 among all the groups, indicating the most significant antiproliferation effect on SMCs. Consistently, the highest expression level of caspase-3 was observed in the same group ( Figure 6B) .
The expression level of the P-ERK1/2 (phosphorylated ERK1/2) was also measured, as previous studies have reported the inhibition of PA remodeling with sildenafil treatment via downregulating the expression of P-ERK1/2 in monocrotaline-induced PAH. 26, 27 The expression level of a primary glycolysis initiator of SMCs, HK-2 (hexokinase-2), 28 was also checked. As expected, a significant decrease on the expression of both P-ERK1/2 and HK-2 was observed after the treatment with the GlcA-sildenafilLips preparation, as shown in the immune-blotting results ( Figure 6C) , confirmed by the quantitative assay ( Figure 6D and 6E).
In addition, both of downregulated eNOS (endothelial nitric oxide synthase) and inactivated cGMP/cGKI signal pathway, which results from overexpression of PDE 5 (phosphodiesterase 5), induce pulmonary arterioles constriction and inhibit the apoptosis of PASMCs in PAH patients. Significantly, GlcA-sildenafil-Lips enabled most profound upregulation of eNOS and cGMP among the formulations (Figures S7 and S8) .
Overall, the treatment with GlcA-sildenafil-Lips could significantly inhibit the PA remodeling via enhanced expression of caspase-3, downregulated expression of HK-2, and increased levels of eNOS and cGMP.
Discussion
PAH is currently a debilitating disease with poor prognosis because the efficacy of drug is compromised because of its poor bioavailability and limited accumulation in the remodeling PAs. The drug-incorporated nanoparticles for pulmonary delivery have been reported to not only improve the drug's efficacy in regression of PAH but also reduce the offside effect. 29 However, the emerging issue is how to target the specific cellular phenotypes in PAH using nanomedicines and, consequently, it is essential to explore the markers on the phenotypes. It was hypothesized that the Warburg effect, resulting from active glycolysis, was present in remodeling PAs, 11 concomitant with the high expression of GLUT-1 and increased uptake of glucose in the lung and RV. 20 However, only a few evidences of this have been reported. Moreover, the remodeling or muscularization of PAs has been reported to be directly associated with increased proliferation of PASMCs. 30 Therefore, promoting the apoptosis of PASMCs has been considered as a promising strategy for PAH treatment. 31, 32 In this study, immunoblot assay on remodeling PAs of monocrotalineinduced PAH showed a significant increase in the expression of GLU-1, especially on PASMCs ( Figure 1B and 1C) . These results led us to investigate a new approach in which the therapeutic agent could be specifically delivered to SMCs aiming to develop a targeted therapy for PAH. Our results show improved accumulation of the nanoparticles in the remodeling PAs and PASMCs when modified with GlcA. Furthermore, besides PASMCs, other cell types, PA endothelial cells, fibroblasts/myofibroblasts, and pericytes, result in the development of PAH as well. 18 Because of the Warburg effect, we cannot exclude the possibility of upregulation of GLU-1 on these cell types. Previous reports indicated that oral administration of sildenafil could inhibit the remodeling of PAs in a PAH model via the upregulation of RhoA (Ras homolog gene family A) and the downregulation of P-ERK1/2 rather than its anti-inflammatory, anti-oxidant, and vasodilation effects. 26, 33 However, owing to the short half-time and systemic adverse effects, the preparation of sildenafil did not significantly improve longterm survival rate in PAH patients. In this study, we developed targeted liposomes (GlcA-Lips) to deliver sildenafil (GlcAsildenafil-Lips) specifically to PASMCs. Compared with the delivery of free sildenafil or sildenafil-Lips, GlcA-sildenafilLips exhibited potent efficacy to inhibit the remodeling of PAs in the monocrotaline-induced PAH, with a reduced PA pressure (32.4%), a decreased medial thickening of PAs (>40%), an improved RV hypertrophy (≈45%), as well as an elevated survival rate in the monocrotaline-induced rats. The improved treatment efficacy of the GlcA-sildenafil-Lips could be explained as follows: (1) the accumulation of the GlcAsildenafil-Lips in the PAs of lungs was enhanced because of its prolonged blood circulation; (2) the cellular uptake of GlcAsildenafil-Lips by SMCs increased because of its affinity to GULT-1; (3) the pro-apoptosis of SMCs increased mainly because of the upregulation of caspase-3; and (4) the proliferation and Warburg effect were attenuated due to the downregulation of P-ERK1/2 and HK-2 and upregulations of eNOS and cGMP. Furthermore, previous reports indicated that sildenafil also enabled effective treatment for other PAH models, such as hypoxia-induced PAH 34 and surgical model, 35 though PAH can be caused by different pathogenesis. Therefore, by targeting the GLUT-1 on SMCs in the remodeling PAs, the developed GlcA-sildenafil-Lips have promising potential to be used as a generalized approach for the treatment of PAH.
Conclusions
In this study, GlcA-Lips were prepared for the targeted delivery of the sildenafil drug to SMCs in remodeled PAs for the treatment of PAH. We first demonstrated the overexpression of GLU-1 on PASMCs in a monocrotaline-induced PAH experimental model. The overexpressed GLU-1 provides a potential target to functionalize liposomes formulations for PAH treatment via a targeted therapeutic approach. Second, improved accumulation of the developed GlcA-Lips was observed in the lung, especially in the PAs of monocrotalineinduced PAH. The accumulated GlcA-Lips could, therefore, inhibit the remodeling process of PAs predominantly via a mechanism of reduction of P-ERK1/2 and HK-2, initiation of the caspase-3 related apoptotic pathway, and increased levels of eNOS and cGMP. This study showed the potential of GlcALips for the targeted delivery of sildenafil to PASMCs and for treating PAH more effectively, suggesting new opportunities for targeted therapies in PAH.
Perspectives
The study demonstrates the expression of GLU-1 on PASMCs in monocrotaline-induced PAH. Additional work is needed to investigate the possibility of the upregulation on other cell types in PAH. Via targeting to the GLU-1 with GlcA-modified liposomes loaded sildenafil, the remodeling process of PAs is inhibited significantly. The platform has promising potential to be a generalized approach for PAH treatment. For translating our present finding into the clinic, more studies are warranted.
